Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells.

Area of Science:

• Oncology
• Immunotherapy
• Cancer Research

Background:

• Chimeric antigen receptor (CAR) T-cell therapy faces challenges in solid tumor targeting, particularly antigen selection.
• Neuroblastoma, a childhood cancer, has shown promise with CAR T-cells targeting GD2 and B7H3.
• Anaplastic lymphoma kinase (ALK) is a potential target for neuroblastoma due to its expression in tumors and limited presence in healthy tissues.

Purpose of the Study:

• To develop novel CAR T-cell constructs targeting anaplastic lymphoma kinase (ALK) for neuroblastoma treatment.
• To investigate strategies for enhancing the efficacy and safety of ALK-targeted CAR T-cells.

Main Methods:

• Generated and screened a single-chain variable fragment library to create anti-ALK CAR T-cell constructs.
• Developed a co-CAR approach combining an ALK-targeting CAR with co-stimulatory receptors (anti-B7H3 or anti-GD2).
• Assessed cytotoxicity, cytokine production, and proliferative responses of engineered T-cells against neuroblastoma cells.

Main Results:

• A novel CAR T-cell construct demonstrated specific cytotoxicity against low-ALK-expressing neuroblastoma cells.
• The co-CAR approach improved T-cell responses and showed potential for mitigating on-target, off-tumor toxicity by avoiding single-antigen targeting.
• Engineered T-cells showed enhanced responses when receiving dual signals from the co-CAR system.

Conclusions:

• Anaplastic lymphoma kinase (ALK) is validated as a viable target antigen for neuroblastoma CAR T-cell therapy.
• The developed co-CAR strategy offers a promising approach to enhance CAR T-cell efficacy and safety in solid tumors.
• Further development of ALK-targeted CAR T-cells, particularly with co-stimulatory elements, holds potential for improved neuroblastoma treatment outcomes.